Okhla, Delhi
- GST NO. : 07ABEFM6994Q2Z7
Gastric Cancer
Leading Exporters and Wholesaler of and Ripretinib Tablets from Delhi.
| Business Type | Exporter, Supplier |
| Form | Tablets |
| Usage | Used to Treat Adults with Advanced Gastrointestinal Stromal Tumor |
| Dosage | As per Doctor's Prescription |
| Storage | Cool and Dry Place |
| Best Before | 36 Months from Manufacturing |
Preferred Buyer From
| Location | Worldwide |
A drug used to treat adults with advanced gastrointestinal stromal tumor. It is used in patients whose cancer was already treated with at least three other kinase inhibitors, including imatinib mesylate. It is also being studied in the treatment of other types of cancer. Ripretinib blocks certain proteins, which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called Qinlock.
Ripretinib is approved to treat: Gastrointestinal stromal tumor that is advanced. It is used in adults whose cancer has been treated with at least three kinase inhibitors, including imatinib mesylate. Ripretinib was approved for medical use in the United States in May 2020, in Australia in July 2020, and in the European Union in November 2021.[5] Ripretinib is the first new drug specifically approved in the United States as a fourth-line treatment for advanced gastrointestinal stromal tumor (GIST).
